Search - tctmd.com

Displaying 21 - 40 of 83

Sort: Relevancy | Date

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 10, 2022

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

News Daily News

New Revascularization Guidelines Plug Radial Access, Staged PCI, and Shorter DAPT

Michael O'Riordan

December 09, 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

June 2021 News Roundup

News Opinion CV Team Dispatch

June 2021 News Roundup

June 01, 2021

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

News Conference News AHA 2020

FIDELIO-DKD: Finerenone Cuts CV Events in Diabetic Kidney Disease

November 16, 2020

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

September 30, 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

September 17, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

August 03, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

Decline in US Deaths From CVD and Diabetes Is Leveling Off

News Daily News

Decline in US Deaths From CVD and Diabetes Is Leveling Off

August 27, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.